EpiCor for Respiratory Symptoms

N/A

Waitlist Available

Led By David Crowley, MD

Research Sponsored by Cargill

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 42 and 84 days

Summary

This trial tests if taking EpiCor daily for about three months can reduce cold or flu symptoms in children aged 4-12 who go to school or daycare. EpiCor is a supplement that may help boost the immune system.

Eligible Conditions

Respiratory Symptoms
Breathing difficulties

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 42 and 84 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 42 and 84 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 42 and 84 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Incidence of cold or flu symptoms

Secondary study objectives

Duration of cold or flu symptoms

Incidence on cold or flu symptoms from baseline to day 42

Number of days prior to first cold or flu symptoms

+10 more

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: EpiCorExperimental Treatment1 Intervention

500 mg EpiCor given as two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.

Group II: PlaceboPlacebo Group1 Intervention

Two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

EpiCor

2015

N/A

~340

Do I qualify?Apply below to find out